Spain Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Spain Breast Cancer Therapeutics Market Analysis

$ 3999

Recent developments in breast cancer therapies and continuous improvement of screening procedures for early detection of breast cancer in Spain drive the Spain breast cancer therapeutics market from $351 Mn in 2022 to $864 Mn in 2030 with a CAGR of 11.9% for the year 2022-2030. The market is segmented by therapy, by cancer type, and by distribution channel. Farmaprojects S.A.U., Novartis AG, and Merck Co & Inc. are the leading players in Spain breast cancer therapeutics market.

ID: IN10ESPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Spain AUTHOR: Parul Choudhary

Buy Now

Spain Breast Cancer Therapeutics Market Executive Analysis

The Spain breast cancer therapeutics market size is at around $351 Mn in 2022 and is projected to reach $864 Mn in 2030, exhibiting a CAGR of 11.9% during the forecast period. The Spanish Ministry of Health's consolidated budget expenditures in 2022 were about $2.6 Bn, down from the $3.5 Bn declared a year earlier. The Ministry of Health's budget expenditures reached their highest point in 2021, rising by more than $3.14 Bn from the previous year when the allocated budget was just over $129.6 Bn. In 2022, around $8.4 Bn of this budget was allotted for employee organization and health policies.

In Spain, about 25 out of every 1,000 women with benign breast illness went on to receive a breast cancer diagnosis. About 15 out of every 1,000 women without benign breast illness received a breast cancer diagnosis. Regardless of age, women with benign breast disease were found to have an increased risk, and the risk persisted for at least 20 years. Breast cancer diagnoses were 99% more likely to occur in women who were followed up for less than four years than they were in those who were followed up for 12 to 20 years.

spain breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

The high incidence and prevalence rates of breast cancer, rising research and development expenditure, and developments in cancer biology and pharmacology, which are encouraging drug development, are the main drivers of the market's expansion in Spain. Furthermore, the Spanish government has undertaken a variety of initiatives to incorporate breast cancer screening programs for early diagnosis.

Market Restraints

The cessation of late-stage clinical trials along with high treatment costs are predicted to severely limit the market for Spain breast cancer therapies. Breast cancer treatment market growth is further impeded by Spain's low healthcare coverage of the disease and rigorous standards for clinical trials.

Competitive Landscape

Key Players

Gynea Laboratorios (ESP)
Biofabri (ESP)
Farmaprojects S.A.U. (ESP)
Novartis AG
Merck Co & Inc.
Fresenius Kabi
Pfizer Inc.

Healthcare Policies and Regulatory Landscape.

The Spanish Ministry of Health establishes criteria for the type of treatments and medications that are covered, as well as the reimbursement rates for hospitals and doctors when it comes to healthcare policies for breast cancer treatment. Private health insurance could also offer further support for the treatment of breast cancer. As a result of Spain's decentralized healthcare system, some reimbursement details may differ depending on the Autonomous Community, but overall, the majority of the costs associated with a breast cancer diagnosis, treatment, and follow-up are covered.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.